Adverse effects of chemotherapeutic agents remain a significant clinical challenge in the management of gastric cancer. Across the literature, discussions of chemotherapy consistently document a range of toxicities, underscoring that even when treatment halts disease progression, it can leave substantial clinical sequelae. Chemotherapy can impact virtually every organ system, producing multiorgan toxicity with meaningful implications for patient quality of life and treatment feasibility. When initiating a new chemotherapy regimen, prior lack of therapeutic benefit is often associated with difficult recovery or inability to tolerate subsequent chemotherapy, thereby constraining future therapeutic options. Given these considerations and the current absence of universally personalized treatment, a multidisciplinary team—comprising a medical oncologist, gastroenterologist, and internist—is essential to the planning and execution of chemotherapy regimens. We recommend that these chemotherapy regimens be administered within internal medicine departments, in collaboration with the medical oncologist and gastroenterologist, because in many cases the adverse effects outweigh the potential benefits of chemotherapy.
化疗药物的不良反应仍然是胃癌治疗中的一项重大临床挑战。文献中关于化疗的讨论普遍记录了一系列毒性反应，强调即使治疗能够阻止疾病进展，也可能留下显著的临床后遗症。化疗几乎可影响所有器官系统，产生多器官毒性，对患者的生活质量和治疗可行性产生重要影响。当启动新的化疗方案时，既往缺乏治疗获益往往与恢复困难或无法耐受后续化疗相关，从而限制了未来的治疗选择。鉴于这些考虑以及目前缺乏普遍个体化治疗的现状，由肿瘤内科医师、消化科医师和内科医师组成的多学科团队对于化疗方案的制定与实施至关重要。我们建议这些化疗方案应在内科科室中，与肿瘤内科医师和消化科医师协作实施，因为在许多情况下，化疗的不良反应可能超过其潜在获益。
Chemotherapy for Gastric Cancer Is Not Solely the Domain of the Oncologist
肿瘤(癌症)患者之家